Alveolar Soft Part Sarcoma Overview

Save information for later
Sign Up

Learn About Alveolar Soft Part Sarcoma

What is the definition of Alveolar Soft Part Sarcoma?
Alveolar soft part sarcoma (ASPS) is a rare, slow-growing soft tissue sarcoma. Although it has been described in a variety of locations, it most commonly develops on the lower extremities in adults and in the head and neck region of children. ASPS generally presents as a soft, pain-less lump that is often not associated with any additional signs and symptoms. In many cases, the condition is not diagnosed until the affected person develops symptoms of metastasis to other sites such as the lungs, bones, central nervous system and/or liver. The underlying cause of ASPS is poorly understood. Most cases occur sporadically in people with no family history of the condition.
What are the alternative names for Alveolar Soft Part Sarcoma?
  • Alveolar soft part sarcoma
  • ASPS
Who are the top Alveolar Soft Part Sarcoma Local Doctors?
Dr. Roscoe H. Chan
Radiation Oncology
Dr. Roscoe H. Chan
Radiation Oncology

Olympic Medical Physicians

844 N 5th Ave, 
Sequim, WA 
 (21.6 mi)
360-683-9895
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roscoe Chan is a Radiation Oncologist in Sequim, Washington. Dr. Chan and is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Myxoid Liposarcoma, and Rhabdomyosarcoma Embryonal. Dr. Chan is currently accepting new patients.

Dr. Junfeng Wang
Hematology Oncology | Oncology | General Surgery
Dr. Junfeng Wang
Hematology Oncology | Oncology | General Surgery

Public Hospital Dist No 1 Skagit

307 S 13th St, Suite 100, 
Mount Vernon, WA 
 (21.6 mi)
360-814-2146
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Junfeng Wang is a Hematologist Oncology specialist and an Oncologist in Mount Vernon, Washington. Dr. Wang and is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Thrombocytopenia, and Multiple Myeloma. Dr. Wang is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Bruce C. Mathey
Oncology | Hematology Oncology | Hematology
Dr. Bruce C. Mathey
Oncology | Hematology Oncology | Hematology

Public Hospital Dist No 1 Skagit

1415 E Kincaid St, 
Mount Vernon, WA 
 (21.6 mi)
360-814-2146
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Mathey is an Oncologist and a Hematologist Oncology provider in Mount Vernon, Washington. Dr. Mathey and is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Mathey is currently accepting new patients.

View All Doctors
What are the latest Alveolar Soft Part Sarcoma Clinical Trials?
A Randomized Phase 2 Study of Atezolizumab With or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
A Randomized Phase 2 Study of Atezolizumab With or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2

Summary: This phase II trial tests whether atezolizumab alone or in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer. The usual approach is defined as care most people get for alveolar soft part sarcoma if they are not part of a clinical study, which includes treatment...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Platform Study of AB122 Based Treatments in Patients with Advanced Solid Tumors
Platform Study of AB122 Based Treatments in Patients with Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 25, 2024
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center